Can You Still Get Compounded Tirzepatide? The Post-Shortage Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Yes, compounded tirzepatide remains available through licensed 503A pharmacies for patients with documented individualized clinical reasons
• The broad shortage-based pathway that drove the 2022-2024 telehealth wave ended on October 2, 2024 when the FDA resolved the tirzepatide shortage
• The legitimate pathway in 2026 requires a valid prescription, documented clinical reason, and a licensed pharmacy partner
• Patients without specific clinical justification are typically directed to brand Mounjaro or Zepbound, including through LillyDirect self-pay options
• Sources operating outside the licensed framework (research-chemical websites, unverified telehealth platforms, gray-market peptide vendors) are not legitimate and carry substantially higher risk

Direct answer

Yes, you can still get compounded tirzepatide, but the pathway is narrower than during the shortage period. A licensed 503A pharmacy can compound tirzepatide for an individual patient when a prescriber documents a specific clinical reason that brand Mounjaro or Zepbound cannot meet. The shortage-based pathway that allowed broad 503B production ended October 2, 2024. The 503A patient-specific pathway is preserved by federal statute and remains available.

Table of contents

1. The "yes, but" answer in detail
2. What changed in October 2024 (and what didn't)
3. The legitimate pathway, step by step
4. Who qualifies for compounded vs brand
5. How to find a legitimate source
6. What compounded tirzepatide costs now
7. Red flags that signal an illegitimate source
8. Brand alternatives worth considering
9. The contrary view: should you seek compounded at all?
10. FAQ
11. Sources

The "yes, but" answer in detail

"Can you still get compounded tirzepatide" is a yes-or-no question that requires a yes-but answer. The full picture:

• Yes: 503A patient-specific compounding remains legal and available
• But: Requires a documented individualized clinical reason
• Yes: Telehealth platforms continue to operate in this space
• But: The intake assessment is more rigorous than during the shortage period
• Yes: Many patients continue compounded therapy without disruption
• But: New patients who do not meet the clinical-reason threshold are now typically directed to brand alternatives

The shift is real but not catastrophic for patients. The pathway looks different than it did in 2023; it has not closed.

What changed in October 2024 (and what didn't)

The FDA removed tirzepatide from its drug shortage list on October 2, 2024, after Eli Lilly's manufacturing capacity caught up with demand. The decision had specific regulatory consequences:

What ended:

• 503B outsourcing facility production of tirzepatide. These FDA-regulated facilities had been the dominant source of high-volume compounded tirzepatide. They could no longer legally compound tirzepatide for office stock without shortage status.
• Shortage-based compounding through 503A pharmacies. Many 503A operations had been compounding tirzepatide using shortage status as the standalone justification. That justification ended.
• API import allowances tied to shortage authority. Some import provisions that applied during shortage no longer applied.

What did not change:

• The Section 503A federal statute, which authorizes patient-specific compounding by licensed pharmacies for individual patients
• The clinical situations that have always justified 503A compounding (allergen sensitivities, dose individualization, formulation requirements)
• State pharmacy board authority over 503A operations within each state
• The right of licensed prescribers to write patient-specific compounded prescriptions when clinically indicated

A federal court ruling on March 5, 2025 (Outsourcing Facilities Association v. FDA, Northern District of Texas) affirmed the FDA's shortage resolution decision. The ruling closed the 503B legal challenge but did not address 503A patient-specific compounding, which operates under different legal authority.

The legitimate pathway, step by step

Here is what the legitimate path looks like in 2026 at a platform like FormBlends:

1. Eligibility assessment. A licensed clinician reviews medical history, weight history, comorbidities, prior medication trials, and current health status. This determines whether tirzepatide is appropriate at all, regardless of brand vs compounded.
2. Brand consideration. If tirzepatide is clinically appropriate, the clinician considers whether brand Mounjaro or Zepbound is the right preparation. This includes evaluating cost (LillyDirect self-pay at $349-$699/month depending on dose), insurance coverage, and clinical fit.
3. Compounded evaluation. If brand is not appropriate for documented clinical reasons, the clinician considers compounded preparation. The chart documents the specific reason: allergen sensitivity to a brand inactive ingredient, dose strength not commercially available, concentration adjustment for tolerability, preservative-free formulation requirement.
4. Pharmacy fulfillment. The prescription routes to a 503A licensed pharmacy in good standing with its state board, operating under USP 797 sterile compounding standards. The pharmacy fills the patient-specific prescription.
5. Shipment and onboarding. The medication ships under cold chain with storage and administration instructions. The platform supports the patient through onboarding and titration.
6. Ongoing review. The prescriber reviews progress, adverse events, and the continued clinical justification for compounded vs brand. Reassessment occurs at regular intervals.

Who qualifies for compounded vs brand

The clinical criteria for tirzepatide therapy in general (BMI 30+ or BMI 27+ with comorbidities for Zepbound; type 2 diabetes for Mounjaro) apply regardless of brand vs compounded. The additional layer is the clinical reason for choosing compounded specifically.

Compounded is often clinically appropriate when:

• The patient has a documented sensitivity to specific inactive ingredients in commercial Mounjaro or Zepbound
• The patient requires a dose strength not available in the commercial product (intermediate titration doses like 1.25 mg or 3.75 mg)
• The patient needs a different concentration to manage injection volume tolerability
• The patient has a documented need for preservative-free preparation
• The patient cannot tolerate the specific buffer or excipient profile of the commercial product

Brand is typically the right choice when:

• The patient meets standard clinical criteria without specific intolerance issues
• Insurance coverage makes brand affordable (most commercial plans for diabetes; some plans for obesity)
• The patient prefers the consistency and clinical trial-backed dosing of the commercial product
• Self-pay through LillyDirect at $349-$699/month fits the patient's budget

How to find a legitimate source

The legitimate source has several markers:

• Named pharmacy partner. A reputable telehealth platform names its pharmacy partner. The pharmacy is licensed in its operating states, has a verifiable physical address, and shows up in state board licensure databases.
• Required clinical intake. Legitimate platforms require a real clinical intake, not a 30-second checkbox form. A licensed clinician reviews the case before any prescription is written.
• Documented clinical reason. The prescriber documents the specific clinical justification for compounded preparation. This is documented in the medical record and on the prescription itself.
• USP 797 compliance. Partner pharmacies operate under USP Chapter 797 standards for sterile compounding, with state board oversight.
• Cold chain shipping. The medication ships refrigerated with documented storage protocols.

What compounded tirzepatide costs now

Pricing has shifted modestly since October 2024.

Source	Typical Monthly Cost (2026)
Compounded tirzepatide (503A) for documented clinical reason	$250-$500
Brand Zepbound through LillyDirect self-pay (2.5 mg vial)	$349
Brand Zepbound through LillyDirect self-pay (5 mg vial)	$499
Brand Zepbound through LillyDirect self-pay (7.5 mg vial)	$599
Brand Zepbound through LillyDirect self-pay (10 mg vial)	$699
Brand Zepbound through commercial insurance with savings card	$25-$200, varies
Brand Zepbound retail pharmacy (uninsured)	$1,000-$1,300

The cost gap between compounded and self-pay brand has narrowed substantively. For patients who previously chose compounded purely on cost grounds, the LillyDirect option may now be competitive.

Red flags that signal an illegitimate source

The following are markers of operations that should be avoided:

• No named pharmacy. The source ships product but won't tell you which licensed pharmacy compounds it.
• "Research only" labeling. Product marked as "for research purposes" or "not for human use" is sold as a research chemical, not as medication. This is not legitimate compounded medicine.
• No prescription required. Federal law requires a valid prescription. Any source bypassing this is operating illegally.
• Crypto-only payment. Legitimate licensed pharmacies accept standard payment methods. Crypto-only is a hallmark of gray-market operations.
• Shipping from outside the U.S. Compounded medication for a U.S. patient should come from a U.S.-licensed pharmacy. Cross-border shipments outside the regulated framework are not legitimate.
• Prices far below the typical range. Compounded tirzepatide at $50/month is almost certainly counterfeit, mis-dosed, or not actually tirzepatide.
• Vague or evasive answers to verification questions. A legitimate source can answer where the API comes from, where the pharmacy is licensed, and what quality testing is performed.

Brand alternatives worth considering

For patients who previously chose compounded, the brand alternatives in 2026 are:

LillyDirect Zepbound vial program: Self-pay access at $349-$699/month depending on dose. Available directly through Eli Lilly's platform. Provides FDA-approved, cGMP-manufactured product with full clinical trial backing.

Commercial insurance coverage: Many plans cover Zepbound for obesity with prior authorization. Manufacturer savings cards can reduce copay to $25/month for eligible commercially-insured patients.

Mounjaro for type 2 diabetes: Broader insurance coverage for the diabetes indication. Most plans cover Mounjaro with typical copay structures.

Other GLP-1 options: Wegovy (semaglutide for obesity), Ozempic (semaglutide for diabetes), Saxenda (liraglutide for obesity) are alternatives with different cost and clinical profiles.

The contrary view: should you seek compounded at all?

A reasonable position: with brand Zepbound now available through LillyDirect at $349-$699/month, the cost-driven case for compounded has weakened. Compounded preparations introduce variability in manufacturing, formulation, and quality that does not improve patient outcomes when brand is accessible.

This view favors brand for nearly all patients, with compounded reserved for the narrow situations where individualized formulation is genuinely clinically necessary (specific allergen sensitivities, unusual dose requirements). The view has support from many endocrinologists and obesity medicine specialists.

The counter: the 503A pathway exists for legitimate reasons, and individual patient circumstances do sometimes justify compounded preparation. Self-pay brand at $499/month is still significant for many patients. The judgment is per-patient, not per-population.

Both positions are defensible. The honest answer for any individual patient depends on their specific clinical situation, financial circumstances, and prescriber's clinical judgment.

Decision framework

If you have been on compounded tirzepatide and want to continue: Ask your prescriber whether the chart documents a clinical reason. If yes, continued access is straightforward. If not, discuss whether transition to brand or development of a documented clinical reason makes sense.

If you are new to tirzepatide: Start with the question of whether you meet clinical criteria. If yes, the default in 2026 is brand Zepbound or Mounjaro, often through LillyDirect self-pay or insurance. Compounded is appropriate for specific clinical situations.

If cost is the primary driver: Compare LillyDirect pricing to compounded pricing for your specific dose. The gap is narrower than many patients realize.

If a source is offering compounded without proper structure: Avoid. Licensed 503A is legitimate; non-licensed sources are not.

FAQ

Can you still get compounded tirzepatide?
Yes, through licensed 503A pharmacies for patients with documented clinical reasons.

Where can I get it legally?
Through a licensed 503A pharmacy filling a valid prescription documenting clinical justification.

Do I need a prescription?
Yes, required by federal law.

What is an individualized clinical reason?
Documented determination that commercial product cannot meet patient's specific clinical needs.

Can my regular doctor prescribe it?
Yes, if licensed and willing to document the clinical reason.

What does it cost in 2026?
Typically $250-$500/month for compounded; $349-$699/month for self-pay brand through LillyDirect.

Is buying compounded tirzepatide online safe?
Depends on whether the source is a licensed 503A pharmacy with verifiable credentials.

How long can I stay on compounded?
As long as clinical justification is documented and continues to apply.

Will compounded tirzepatide be banned?
An outright ban would require Congressional action; no legislation pending.

Does FormBlends still offer it?
Yes, through 503A pharmacy partners with documented clinical justification.

Sources

1. FDA Drug Shortage List update, October 2, 2024, resolving tirzepatide shortage
2. Federal Food, Drug, and Cosmetic Act Section 503A, 21 U.S.C. § 353a
3. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
4. Outsourcing Facilities Association v. FDA, Northern District of Texas ruling, March 5, 2025
5. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
6. Eli Lilly LillyDirect platform pricing and product information
7. FDA Guidance, "Compounding and the FDA: Questions and Answers"
8. National Association of Boards of Pharmacy compounding standards
9. State Board of Pharmacy licensure verification databases (50 states)
10. Zepbound FDA prescribing information, November 2023 with updates
11. Mounjaro FDA prescribing information, May 2022 with updates

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform that connects patients with licensed clinicians and 503A compounding pharmacies. We do not practice medicine, dispense, or manufacture. Prescribing and compounding decisions are made by licensed professionals.

Compounded Medication Notice. Compounded tirzepatide is prepared by licensed 503A pharmacy partners for individual patients based on prescriber-documented clinical reasons. The product is not FDA-approved and is not regulatorily equivalent to brand Mounjaro or Zepbound. SURMOUNT trial data applies to brand product specifically.

Results Disclaimer. Individual response varies significantly. SURMOUNT-1 reported a 22.5% mean weight loss at 15 mg over 72 weeks in a controlled trial; your real-world result will differ based on dose, adherence, baseline weight, and individual physiology.

Trademark Notice. Mounjaro, Zepbound, SURMOUNT, and LillyDirect are trademarks or service marks of Eli Lilly and Company. FormBlends is independent and not affiliated with Eli Lilly.